Immunotherapies in acute leukemia

Nicolas Boissel; Florence Rabian

doi:10.1016/j.therap.2021.12.003

Immunotherapies in acute leukemia

Therapie. 2022 Mar-Apr;77(2):241-250. doi: 10.1016/j.therap.2021.12.003. Epub 2021 Dec 6.

Authors

Nicolas Boissel¹, Florence Rabian²

Affiliations

¹ Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; URP-3518, Institut de Recherche Saint-Louis, Université de Paris, 75010 Paris, France. Electronic address: nicolas.boissel@aphp.fr.
² Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; URP-3518, Institut de Recherche Saint-Louis, Université de Paris, 75010 Paris, France.

PMID: 34924207
DOI: 10.1016/j.therap.2021.12.003

Abstract

In the past decade, immunotherapy has emerged as one of the most promising field of therapeutic progress in acute leukemia. Antibody-drug conjugates are now combined to standard chemotherapy backbones in both acute myeloid (AML) and lymphoblastic leukemia (ALL). CD19 targeting immune cell engagers and chimeric antigen receptor (CAR) T-cells have been approved in relapsed/refractory B-cell acute lymphoblastic leukemia and pave the way to promising developments in acute myeloid leukemia. Next generation immune checkpoint inhibitors targeting TIM-3 or CD47 binding by SIRPα on macrophages are tested in combination to hypomethylating agents to improve survival of unfit AML patients with acceptable safety profiles. This review summarizes the antibody-derived strategies developed in the field of acute leukemias with a specific focus on recently approved drugs.

Keywords: Acute lymphoblastic leukemia; Acute myeloid leukemia; Antibody; Bispecific antibody; CAR-T; Immunotherapy.

Publication types

Review

MeSH terms

Antigens, CD19 / therapeutic use
Humans
Immunotherapy
Leukemia, Myeloid, Acute* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy

Substances

Antigens, CD19